Patents Examined by Robert M. Kelly
  • Patent number: 10793861
    Abstract: The present invention relates to RNA-based methods for inhibiting the expression of the superoxide dismutase 1 (SOD-1) gene. Recombinant adeno-associated viruses of the invention deliver DNAs encoding RNAs that knock down the expression of SOD-1. The methods have application in the treatment of amyotrophic lateral sclerosis.
    Type: Grant
    Filed: July 20, 2018
    Date of Patent: October 6, 2020
    Assignees: RESEARCH INSTITUTE AT NATIONWIDE CHILDREN'S HOSPITAL, LUDWIG INSTITUTE FOR CANCER RESEARCH
    Inventors: Brian K. Kaspar, Kevin Foust, Don W. Cleveland
  • Patent number: 10792251
    Abstract: Liposomes termed as small unilamellar vesicles (SUVs), can be synthesized in the 20-50 nm size range, but encounter challenges such as instability and aggregation leading to inter-particle fusion. This limits their use as a therapeutic delivery agent. Increasing the surface negative charge of SUVs, via the attachment of anionic entities such as DNA/RNA, increases the colloidal stability of these vesicles. Additionally, the dense spherical arrangement and radial orientation of nucleic acids exhibits unique chemical and biological properties, unlike their linear counterparts. These liposomal particles, are non-toxic and though anionic, can efficiently enter cells without the aid of ancillary cationic transfection agents in a non-immunogenic fashion. These exceptional properties allow their use as delivery agents for gene regulation in different therapies and offer an alternative platform to metal core spherical nucleic acids.
    Type: Grant
    Filed: January 8, 2019
    Date of Patent: October 6, 2020
    Assignees: NORTHWESTERN UNIVERSITY, EXICURE, INC.
    Inventors: Chad A. Mirkin, Sonbinh T. Nguyen, Resham Singh Banga, Natalia Chernyak, Sergei Gryaznov, Aleksandar Radovic-Moreno, Christopher Mader
  • Patent number: 10792375
    Abstract: A method of treating cancerous tumors is presented herein. The method includes injecting an effective dose of a plasmid encoded for IL-12, B7-1 or IL-15 into a cancerous tumor and subsequently administering at least one high voltage, short duration pulse to the tumor. The electroporation pulses may be administered at al least 700 V/cm for a duration of less than 1 millisecond. The intratumor treatments with electroporation may be administered in at least a two-treatment protocol with the time between treatments being about 7 days. The intratumor treatments with electroporation may be administered in a three-treatment protocol with a time of four days between the first and second treatments and a time of three days between the second and third treatments. It was found that the intratumor treatments using electroporation not only resulted in tumor regression but also induced an immune memory response which prevented the formation of new tumors.
    Type: Grant
    Filed: December 3, 2018
    Date of Patent: October 6, 2020
    Assignee: University of South Florida
    Inventors: Richard Heller, Kenneth E. Ugen
  • Patent number: 10786546
    Abstract: A composition comprising a gene therapy product for use in the treatment of a dystrophic disease in a subject, advantageously in humans, wherein: the gene therapy product comprises a nucleic acid sequence encoding a functional microdystrophin; the composition is systemically administered.
    Type: Grant
    Filed: November 9, 2018
    Date of Patent: September 29, 2020
    Assignees: GENETHON, ROYAL HOLLOWAY AND BEDFORD NEW COLLEGE
    Inventors: George Dickson, Thomas Voit, Philippe Moullier, Caroline Le Guiner
  • Patent number: 10767215
    Abstract: The present invention provides a composition and method for stabilizing ribonucleic acid (RNA) from biological samples such that the ribonucleic acid within the sample remains stable at room temperature. The composition comprises an anionic detergent and a buffering agent at a pH of about 5 to about 8.2 and is used in methods for extracting and storing ribonucleic acid from the biological sample.
    Type: Grant
    Filed: May 15, 2018
    Date of Patent: September 8, 2020
    Assignee: DNA GENOTEK INC.
    Inventors: Hyman Chaim Birnboim, Adele Jackson
  • Patent number: 10760098
    Abstract: The present invention is directed to non-naturally occurring peptides containing a membrane-penetrating amino acid sequence and further at least one polycationic moiety or peptide sequence. The peptides are suitable for use in delivery a cargo to the interior of a cell. Suitable cargo includes nucleic acid molecules (including DNA, RNA or PNA), polypeptides, or other biologically active molecules. The present invention is further directed to transfection complexes containing the non-naturally occurring peptides of the present invention in non-covalent association with at least one cationic lipid and a cargo to be delivered to the interior of a cell. The invention further relates to methods for the preparation and use of the non-naturally occurring peptides for the formation of transfection complexes and the delivery of a cargo to the interior of a cell in culture, an animal or a human. The invention also relates to compositions and kits useful for transfecting cells.
    Type: Grant
    Filed: November 13, 2017
    Date of Patent: September 1, 2020
    Assignee: LIFE TECHNOLOGIES CORPORATION
    Inventor: Xavier de Mollerat du Jeu
  • Patent number: 10760061
    Abstract: The nuclear reprogramming of somatic cells with mRNA encoding reprogramming factors is shown to be greatly accelerated by activation of innate immune responses in the somatic cell. Methods of activating innate immunity include activation of PKR, of toll-like receptors, e.g. TLR3, etc. In some embodiments the mRNA provides the activator of innate immunity.
    Type: Grant
    Filed: April 5, 2017
    Date of Patent: September 1, 2020
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: John P. Cooke, Eduard Yakubov
  • Patent number: 10744170
    Abstract: Human clinical use of a chimeric poliovirus construct has demonstrated excellent anti-tumor effect. Combination with immune checkpoint inhibitors increases the anti-tumor effect. Tumors of different types are susceptible to the combination treatment, including but not limited to melanoma, glioglastoma, renal cell carcinoma, prostate cancer, breast cancer, lung cancer, medulloblastoma, and colorectal cancer.
    Type: Grant
    Filed: October 14, 2016
    Date of Patent: August 18, 2020
    Assignee: Duke University
    Inventors: Darell D. Bigner, Matthias Gromeier, Smita Nair, Vidyalakshmi Chandramohan
  • Patent number: 10746728
    Abstract: Existence of human trophoblast stem (hTS) cells has been suspected but unproved. The isolation of hTS cells is reported in the early stage of chorionic villi by expressions of FGF4, FGFR-2, Oct4, Thy-1, and stage-specific embryonic antigens distributed in different compartments of the cell. hTS cells are able to derive into specific cell phenotypes of the three primitive embryonic layers, produce chimeric reactions in mice, and retain a normal karyotype and telomere length. In hTS cells, Oct4 and fgfr-2 expressions can be knockdown by bFGF. These facts suggest that differentiation of the hTS cells play an important role in implantation and placentation. hTS cells could apply to human cell differentiation and for gene and cell-based therapies.
    Type: Grant
    Filed: February 9, 2018
    Date of Patent: August 18, 2020
    Assignee: ACCELERATED BIOSCIENCES CORP.
    Inventors: Jau-Nan Lee, Tony Tung-Ying Lee, Yuta Lee
  • Patent number: 10738282
    Abstract: The finding that phosphatidylserine (PtdSer) exposure on the outer leaflet of virally transduced cells triggers their engulfment by resident immune cells is described. It is demonstrated that inhibition of phospholipid scramblase 1 (PLSCR1) activity prevents PtdSer externalization and enables prolonged protection of vector-transduced cells from phagocytosis. Methods of inhibiting a virus vector-induced inflammatory response in tissue, methods of prolonging virus vector encoded transgene expression, and methods of modulating an inflammatory response in tissue of a subject, by administering an inhibitor of PLSCR1 are described.
    Type: Grant
    Filed: December 20, 2017
    Date of Patent: August 11, 2020
    Assignee: Salk Institute for Biological Studies
    Inventors: Axel Nimmerjahn, Charles L. Clark
  • Patent number: 10731165
    Abstract: Disclosed herein are RNA molecules with particular nucleotide sequences that, through Watson-Crick base pairing, enable the RNAs to form a hydrogel.
    Type: Grant
    Filed: October 6, 2017
    Date of Patent: August 4, 2020
    Assignee: THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK
    Inventors: Li Niu, Zhen Huang
  • Patent number: 10724094
    Abstract: A method of conjugating a substrate includes exchanging a counter ion associated with a biomolecule with a lipophilic counter ion to form a biomolecule complex, dispersing the biomolecule complex in a nonaqueous solvent, and coupling the biomolecule complex to a substrate in the presence of the nonaqueous solvent.
    Type: Grant
    Filed: April 4, 2018
    Date of Patent: July 28, 2020
    Assignee: LIFE TECHNOLOGIES CORPORATION
    Inventors: Steven M. Menchen, Alan Blanchard, Luisa Andruzzi, Shaheer H. Khan, Dmitriy Gremyachinskiy, Alfred Lui, Craig Stolarczyk, Tanya Sokolsky, Prasanna Krishnan Thwar
  • Patent number: 10722463
    Abstract: A method of delivering a pharmaceutical agent into a target organ protected by a blood barrier is provided. The method comprising administering to a subject in need thereof an amount of liposomes which comprise the pharmaceutical agent, the amount and the liposomes are selected such that the liposomes accumulate in cells of an immune system of the subject to thereby generate liposome loaded immune cells, the liposome loaded immune cells become activated and cross the blood barrier, and an effective amount of the pharmaceutical agent is released from the liposomes in the target organ of the subject.
    Type: Grant
    Filed: March 6, 2018
    Date of Patent: July 28, 2020
    Assignee: Zuli Holdings Ltd.
    Inventors: Gershon Golomb, Hila Epstein, Eyal Afergan
  • Patent number: 10711250
    Abstract: The technology relates in part to methods and compositions for ex vivo proliferation and expansion of epithelial cells.
    Type: Grant
    Filed: March 14, 2018
    Date of Patent: July 14, 2020
    Assignee: PROPAGENIX INC.
    Inventor: Chengkang Zhang
  • Patent number: 10711251
    Abstract: The technology relates in part to methods and compositions for ex vivo proliferation and expansion of epithelial cells.
    Type: Grant
    Filed: March 14, 2018
    Date of Patent: July 14, 2020
    Assignee: PROPAGENIX INC.
    Inventor: Chengkang Zhang
  • Patent number: 10701911
    Abstract: The present invention relates generally to genetically modified non-human animals and immunodeficient non-human animals characterized by restored complement-dependent cytotoxicity, as well as methods and compositions for assessment of therapeutic antibodies in the genetically modified immunodeficient non-human animals. In specific aspects, the present invention relates to immunodeficient non-obese diabetic (NOD), A/J, A/He, AKR, DBA/2, NZB/BIN, B10.D2/oSn and other mouse strains genetically modified to restore complement-dependent cytotoxicity which is lacking in the unmodified immunodeficient mice. In further specific aspects, the present invention relates to NOD.Cg-Prkdcscid IL2rgtm1Wjl/SzJ (NSG), NOD.Cg-Rag1tm1Mom IL2rgtm1Wjl/SzJ (NRG) and NOD.Cg-Prkdcscid IL2rgtm1Sug/JicTAc (NOG) mice genetically modified to restore complement-dependent cytotoxicity which is lacking in unmodified NSG, NRG and NOG mice.
    Type: Grant
    Filed: June 16, 2016
    Date of Patent: July 7, 2020
    Assignees: The Jackson Laboratory, University of Massachusetts
    Inventors: Leonard D. Shultz, Mohit Kumar Verma, Dale L. Greiner, Michael A. Brehm
  • Patent number: 10696985
    Abstract: A diblock copolymer, polymer vesicle, and method of forming a polymer vesicle are provided. The diblock polymer includes a hydrophilic first block and a second block including amine containing monomers and hydrophobic monomers. The polymer vesicle includes a diblock copolymer with a hydrophilic first block and a second block including amine containing monomers and hydrophobic monomers, and at least one active agent loaded in the polymer vesicle. The second block forms an inner hydrophobic domain of a vesicle membrane and the hydrophilic block forms a corona facing the exterior and aqueous interior of the vesicle membrane, the corona providing an outer shell that stabilizes the vesicle in aqueous media.
    Type: Grant
    Filed: June 6, 2017
    Date of Patent: June 30, 2020
    Assignee: Vanderbilt University
    Inventors: John T. Wilson, Daniel Shae
  • Patent number: 10668172
    Abstract: The present application provides methods of preventing and treating the toxic effects of exposure to organophosphate agents. In embodiments, targeted cationic liposome complexes delivering nucleic acid molecules encoding butyrylcholinesterase and a polyproline rich peptide are administered. Suitably, the administration is via inhalation or via aerosol. Also provided are cationic liposome complexes and methods of making the complexes for such administration.
    Type: Grant
    Filed: December 14, 2017
    Date of Patent: June 2, 2020
    Assignee: GEORGETOWN UNIVERSITY
    Inventors: Esther H. Chang, Kathleen F. Pirollo
  • Patent number: 10667500
    Abstract: The invention provides double knockout transgenic pigs (GT/CMAH-KO pigs) lacking expression of any functional ?GAL and CMAH. Double knockout GT/CMAH-KO transgenic organs, tissues and cells are also provided. Methods of making and using the GT/CMAH-KO pigs and tissue are also provided.
    Type: Grant
    Filed: December 20, 2017
    Date of Patent: June 2, 2020
    Assignee: Indiana University Research and Technology Corporation
    Inventor: A. Joseph Tector
  • Patent number: 10660922
    Abstract: Cell based therapy comprises administration to the lung by injection into the blood system of viable, mammalian cells effective for alleviating or inhibiting pulmonary disorders. The cells may express a therapeutic transgene or the cells may be therapeutic in their own right by inducing regenerative effects.
    Type: Grant
    Filed: November 8, 2017
    Date of Patent: May 26, 2020
    Assignee: Northern Therapeutics Inc.
    Inventor: Duncan John Stewart